Psychiatry News and Research

RSS

Psychiatry is the treatment, study and prevention of mental disorders.

New research shows hyperactivity in boys may interfere with night-time sleep

Hyperactive boys don't get enough sleep, which can worsen their condition according to new research. Published in the November issue of Pediatrics, the study is the first to examine a large sample of children and to study the link between lack of sleep and hyperactivity.

1 Dec 2009

Eli Lilly's Cymbalta receives FDA approval

The U.S. Food and Drug Administration (FDA) has approved Cymbalta® (duloxetine HCl) for the maintenance treatment of generalized anxiety disorder (GAD) in adults, announced Eli Lilly and Company (NYSE: LLY).

30 Nov 2009

Early intervention for young children with autism improves IQ, communication and social interaction

A novel early intervention program for very young children with autism - some as young as 18 months - is effective for improving IQ, language ability, and social interaction, a comprehensive new study has found.

30 Nov 2009

GIS scientists publish the first genetic historical map of Han Chinese

The first genetic historical map of the Han Chinese, the largest ethnic population in the world, as they migrated from south to north over evolutionary time was published online today by the American Journal of Human Genetics by scientists at the Genome Institute of Singapore (GIS).

26 Nov 2009

Inhaled carbon dioxide increases brain acidity and evokes fear behavior: Study

Breathing carbon dioxide can trigger panic attacks, but the biological reason for this effect has not been understood. A new study by University of Iowa researchers shows that carbon dioxide increases brain acidity, which in turn activates a brain protein that plays an important role in fear and anxiety behavior.

26 Nov 2009

Behavior problems in children with autism can be reduced with a training program for parents

The serious behavior problems that can occur in children with autism and related conditions can be reduced with a treatment plan that includes medication combined with a structured training program for parents, according to Yale University researchers and their colleagues.

26 Nov 2009

Pharmacy-based intervention improves antipsychotic adherence among patients with mental illnesses

Health systems should consider pharmacy-based interventions when involving patients who have poor follow-through taking medication.

24 Nov 2009

Foods rich in antioxidant substances could delay the onset of Alzheimer's disease

Universitat Autònoma de Barcelona (UAB) researchers have confirmed that a diet rich in polyphenols and polyunsaturated fatty acids, patented as an LMN diet, helps boost the production of the brain's stem cells -neurogenesis- and strengthens their differentiation in different types of neuron cells.

23 Nov 2009

Scientists discover new potential target for treating non-Hodgkin's lymphoma

Physician-scientists from Weill Cornell Medical College have discovered a molecular mechanism that may prove to be a powerful target for the treatment of non-Hodgkin's lymphoma, a type of cancer that affects lymphocytes, or white blood cells. By exploiting this mechanism, researchers have been able to powerfully suppress tumor formation in lab testing and in animal models.

22 Nov 2009

Emotionally abused children may face accelerated cellular aging as adults

Children who suffer physical or emotional abuse may be faced with accelerated cellular aging as adults, according to new research from Butler Hospital and Brown University.

21 Nov 2009

FDA approves Pfizer's Geodon Capsules for the adjunctive maintenance treatment of bipolar disorder

Pfizer today announced that the U.S. Food and Drug Administration (FDA) has approved Geodon® (ziprasidone HCI) Capsules for maintenance treatment of bipolar I disorder as an adjunct to lithium or valproate in adults. The approval is based on clinical data demonstrating that Geodon is an effective and generally well-tolerated adjunctive treatment for long-term symptom control in patients with bipolar disorder.

21 Nov 2009

New report finds positive association between phthalate exposure and ADHD symptoms

Phthalates are important components of many consumer products, including toys, cleaning materials, plastics, and personal care items. Studies to date on phthalates have been inconsistent, with some linking exposure to these chemicals to hormone disruptions, birth defects, asthma, and reproductive problems, while others have found no significant association between exposure and adverse effects.

19 Nov 2009

Patients with recent-onset schizophrenia have raised levels of inflammatory substances

Researchers at the Swedish medical university Karolinska Institutet have discovered that patients with recent-onset schizophrenia have higher levels of inflammatory substances in their brains. Their findings offer hope of being able to treat schizophrenia with drugs that affect the immune system.

18 Nov 2009

A fact-based media briefing on bipolar disorder in Nova Scotia

An estimated 26,000 Nova Scotians live with bipolar disorder. Often stigmatized in popular culture, the experience of bipolar disorder varies from one person to the next and almost always has a drastic impact on how individuals think, behave and function.

18 Nov 2009

Depression is as much of a risk factor for mortality as smoking, says new study

A study by researchers at the University of Bergen, Norway, and the Institute of Psychiatry (IoP) at King's College London has found that depression is as much of a risk factor for mortality as smoking.

17 Nov 2009

Shire publishes new study results on INTUNIV Extended-Release Tablets

Shire plc, the global specialty biopharmaceutical company, announced new study results on INTUNIV- (guanfacine) Extended-Release Tablets published in the October Journal of Child and Adolescent Psychopharmacology. In this open-label safety study, there was no evidence of unique adverse effects with the combination of INTUNIV and amphetamine or methylphenidate relative to what was observed with either medication alone.

17 Nov 2009

Results of Phase III clinical trials of flibanserin for treatment of HSDD in pre-menopausal women released

Data from pivotal Phase III clinical trials demonstrate that flibanserin 100mg increased the number of satisfying sexual events (SSE) and sexual desire (the co-primary endpoints) while decreasing the distress associated with Hypoactive Sexual Desire Disorder (HSDD).

16 Nov 2009

Alkermes' phase 3 trial of naltrexone XR-NTX meets primary endpoint

Alkermes, Inc. today announced positive preliminary results from a phase 3 clinical trial of naltrexone for extended-release injectable suspension (XR-NTX) for the treatment of opioid dependence. The six-month phase 3 study met its primary efficacy endpoint and data showed that patients treated once-monthly with XR-NTX demonstrated statistically significant higher rates of clean (opioid-free) urine screens, compared to patients treated with placebo, as measured by the cumulative distribution of clean urine screens (p<0.0002).

16 Nov 2009

Findings from post hoc analysis examining emotional lability from Phase 3 study data with Vyvanse announced

Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced findings from a post hoc analysis examining emotional lability from Phase 3 study data with Vyvanse-. In this study, Vyvanse demonstrated significant improvement in Attention-Deficit/Hyperactivity Disorder (ADHD) symptoms as measured by the ADHD Rating Scale IV (ADHD-RS IV) and Connors' Parent Rating Scale-Revised Short (CPRS-RS) in children with ADHD aged 6 to 12 years.

16 Nov 2009

Chronic pain patients with depression three times more likely to receive opioid medications

Chronic pain patients with a history of depression are three times more likely to receive long-term prescriptions for opioid medications like Vicodin compared to pain patients who do not suffer from depression, according to new research.

16 Nov 2009

Psychiatry News and Research

Further Reading

New research shows hyperactivity in boys may interfere with night-time sleep

Eli Lilly's Cymbalta receives FDA approval

Early intervention for young children with autism improves IQ, communication and social interaction

GIS scientists publish the first genetic historical map of Han Chinese

Inhaled carbon dioxide increases brain acidity and evokes fear behavior: Study

Behavior problems in children with autism can be reduced with a training program for parents

Pharmacy-based intervention improves antipsychotic adherence among patients with mental illnesses

Foods rich in antioxidant substances could delay the onset of Alzheimer's disease

Scientists discover new potential target for treating non-Hodgkin's lymphoma

Emotionally abused children may face accelerated cellular aging as adults

FDA approves Pfizer's Geodon Capsules for the adjunctive maintenance treatment of bipolar disorder

New report finds positive association between phthalate exposure and ADHD symptoms

Patients with recent-onset schizophrenia have raised levels of inflammatory substances

A fact-based media briefing on bipolar disorder in Nova Scotia

Depression is as much of a risk factor for mortality as smoking, says new study

Shire publishes new study results on INTUNIV Extended-Release Tablets

Results of Phase III clinical trials of flibanserin for treatment of HSDD in pre-menopausal women released

Alkermes' phase 3 trial of naltrexone XR-NTX meets primary endpoint

Findings from post hoc analysis examining emotional lability from Phase 3 study data with Vyvanse announced

Chronic pain patients with depression three times more likely to receive opioid medications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News